West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter. Asian Pacific Journal of Cancer Prevention 1513-7368 20 10 2019 10 01 Fecal Genetic Mutations and Human DNA in Colorectal Cancer and Polyps Patients 2929 2934 88760 10.31557/APJCP.2019.20.10.2929 EN Jacqueline Lima Oncology Group, Gastroenterology Division, Medicine Department, Universidade Federal de Sao Paulo, São Paulo, Brazil. Yolanda Teixeira Oncology Group, Gastroenterology Division, Medicine Department, Universidade Federal de Sao Paulo, São Paulo, Brazil. Célia Pimenta Oncology Group, Gastroenterology Division, Medicine Department, Universidade Federal de Sao Paulo, São Paulo, Brazil. Aledson Vitor Felipe Oncology Group, Gastroenterology Division, Medicine Department, Universidade Federal de Sao Paulo, São Paulo, Brazil. 0000-0003-1335-1478 Tiago Donizetti Silva Oncology Group, Gastroenterology Division, Medicine Department, Universidade Federal de Sao Paulo, São Paulo, Brazil. Ermelindo Ermelindo Della Libera Junior Gastroenterology Division and Endoscopist, Universidade Federal de Sao Paulo, São Paulo, Brazil. Sarhan Sydney Saad Surgery Department, Universidade Federal de Sao Paulo, São Paulo, Brazil. Elisabeth Deak Surgery Department, Universidade Federal de Sao Paulo, São Paulo, Brazil. Helena Murray Randox Laboratories Ltd., Crumlin, Co. Antrim, United Kingdom. Nora Manoukian Forones Oncology Group, Gastroenterology Division, Medicine Department, Universidade Federal de Sao Paulo, São Paulo, Brazil. Journal Article 2019 02 12 Background: Colorectal cancer (CRC) is one of the most frequent cancers. Genetic mutations in CRC already described can be detected in feces. Microarray methods in feces can represent a new diagnostic tool for CRC and significant improvement at public health. Aim: to analyze stool DNA by human DNA quantify and microarray methods as alternatives to CRC screening. Method: Three methods were analyzed in stool samples: Human DNA Quantify, RanplexCRC and KRAS/BRAF/PIK3CA (KBP) Arrays. Results: KBP array mutations were presented in 60.7% of CRC patients and RanplexCRC Array mutations in 61.1% of CRC patients. Sensitivity and specificity for human DNA quantification was 66% and 82% respectively. Fecal KBP Array had 35% sensitivity and 96% specificity and RanplexCRC Array method had 78% sensitivity and 100% specificity. Conclusion: Microarray methods showed promise as potential biomarkers for CRC screening; however, these methods had to be optimized to improve accuracy and applicability by clinical routine. https://journal.waocp.org/article_88760_7da7aca6b155735e8c4a021f473498ce.pdf